New sign-up rates for plan selections total 18%.
Over 20 million Americans have broken enrollment records by signing up for individual market healthcare insurance plans for 2024, according to a report from the Centers for Medicare & Medicaid Services (CMS). Last year, only 16.3 million Americans opted in.
Enrollment, which opened on Nov. 1, includes 15.5 million marketplace selections from the 32 states that use the HealthCare.gov platform and 4.8 million selections from the 18 states and the District of Columbia using state-based marketplaces (SBMs).
When combined, more than 3.7 million selections (18%) are from new customers.
“This year’s plan selection is a record-breaking achievement. It shows how far we’ve come and how much this Administration values and is continuing to build on the legacy of the Affordable Care Act nearly 14 years since it was first passed,” CMS Administrator Chiquita Brooks-LaSure in a news release.
Those who have yet to sign up and live in states using the HealthCare.gov platform have until midnight on Jan. 16 to enroll for coverage that begins Feb. 1. Deadlines vary for consumers using an SBM enrollment system.
2023 Drug Trend Report - Xevant
May 16th 2024To effectively navigate the changing pharmacy landscape and maintain a robust, cost-effective pharmacy benefit, you must understand the forces behind rising drug trend. What’s driving your costs and what can you do about it? As a leader in the PBM analytics space, we offer a unique perspective on pivotal trend drivers. Here’s what our comprehensive analysis revealed: -A surge in utilization rates across specialty and non-specialty drugs, magnified by anti-obesity therapies -Financial strain imposed by anti-inflammatory biologics and the yet-to-be-fulfilled -promise of biosimilar savings -Persistent price inflation driving higher costs year over year
Read More
Two Opdivo Updates from Bristol Myers Squibb
May 14th 2024First approved by the U.S. Food and Drug Administration (FDA) in 2014, Opdivo has multiple indications across various types of cancer, including NSCLC, melanoma, renal cell carcinoma, Hodgkin lymphoma, squamous cell carcinoma of the head and neck, and urothelial carcinoma.
Read More